The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment.

[1]  U. Langsenlehner,et al.  The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients , 2015, World Journal of Urology.

[2]  Jeong Eon Lee,et al.  Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology , 2015, Tumor Biology.

[3]  Yongxiang Zhao,et al.  Anti-tumor immune response of folate-conjugated chitosan nanoparticles containing the IP-10 gene in mice with hepatocellular carcinoma. , 2014, Journal of biomedical nanotechnology.

[4]  Ping Chen,et al.  Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer , 2014, Medical Oncology.

[5]  K. Pummer,et al.  Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. , 2014, The Journal of urology.

[6]  H. Samonigg,et al.  The elevated pre‐operative plasma fibrinogen level is an independent negative prognostic factor for cancer‐specific, disease‐free and overall survival in soft‐tissue sarcoma patients , 2014, Journal of surgical oncology.

[7]  K. Pummer,et al.  High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients , 2013, British Journal of Cancer.

[8]  Suzy Kim,et al.  Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy , 2012, International Journal of Clinical Oncology.

[9]  B. Ljung,et al.  Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. , 2012, The Journal of the National Comprehensive Cancer Network.

[10]  V. Bobek.  Anticoagulant and fibrinolytic drugs - possible agents in treatment of lung cancer? , 2012, Anti-cancer agents in medicinal chemistry.

[11]  L. Tang,et al.  High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer , 2010, Journal of surgical oncology.

[12]  Julio Fernández,et al.  Platelet count: association with prognosis in lung cancer , 2010, Medical oncology.

[13]  G. Heinze,et al.  Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. , 2009, American journal of obstetrics and gynecology.

[14]  S. Hao,et al.  Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity , 2009, Cancer science.

[15]  H. Nagawa,et al.  Effect of Preoperative Hyperfibrinogenemia on Recurrence of Colorectal Cancer Without a Systemic Inflammatory Response , 2009, World Journal of Surgery.

[16]  Qiu-ping Xie,et al.  Elevated Levels of Plasma Fibrinogen in Patients With Pancreatic Cancer: Possible Role of a Distant Metastasis Predictor , 2009, Pancreas.

[17]  A. Sahni,et al.  Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor‐2 (FGF‐2) , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  M. Pepys,et al.  Human plasma fibrinogen is synthesized in the liver. , 2007, Blood.

[19]  Min Guo,et al.  Interleukin-1β but not IL-1α binds to fibrinogen and fibrin and has enhanced activity in the bound form , 2004 .

[20]  V. Bobek,et al.  Antitumor and antimetastatic effect of warfarin and heparins. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  L. Magnelli,et al.  Angiogenesis and the unique nature of tumor matrix , 2002, Molecular biotechnology.

[22]  T. Tsuruo,et al.  Clustered cancer cells show a distinct adhesion behavior from single cell form under physiological shear conditions. , 2001, Journal of experimental & clinical cancer research : CR.

[23]  B. Rybarczyk,et al.  Tumors and Fibrinogen , 2001, Annals of the New York Academy of Sciences.

[24]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[25]  A. Sahni,et al.  Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. , 2000, Blood.

[26]  T. Bugge,et al.  Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. , 2000, Blood.

[27]  Hong-Hee Kim,et al.  Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis , 2000 .

[28]  B. Echtenacher,et al.  Lysis of tumor cells by natural killer cells in mice is impeded by platelets. , 1999, Cancer research.

[29]  F. Tablin,et al.  Effect of recombinant interleukin-6 and thrombopoietin on isolated guinea pig bone marrow megakaryocyte protein phosphorylation and proplatelet formation. , 1997, Blood cells, molecules & diseases.

[30]  Thomas E. Moritz,et al.  Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of veterans affairs cooperative study 188 , 1995, American journal of hematology.

[31]  T. Tamada,et al.  Macrophage colony-stimulating factor enhances platelet recovery following cisplatin/carboplatin chemotherapy in ovarian cancer. , 1994, Gynecologic oncology.

[32]  H. Dvorak,et al.  Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation a , 1992, Annals of the New York Academy of Sciences.

[33]  T. Uchida,et al.  Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. , 1990, Blood.

[34]  H. Dvorak,et al.  Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. , 1988, The American journal of pathology.

[35]  F. Rickles,et al.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.

[36]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[37]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[38]  Walz Da,et al.  The role of thrombin in tumor cell metastasis. , 1994 .